Abstract 639P
Background
Maintenance therapy with fluoropyrimidines (such as capecitabine [Cap]) following induction therapy is wildly recommended to unresectable mCRC patients. Fruquintinib (Fru) is a highly selective inhibitor of VEGFR1/2/3 with conspicuous safety and efficacy in mCRC. We sought to evaluate and compare the therapeutic potential of Fru plus Cap (FC) versus Cap as maintenance therapy for mCRC.
Methods
Eligibility criteria included: histologically confirmed mCRC (stage IV), age ≥ 18 years, ECOG PS 0-2, achieved disease control (including CR/PR and SD) after ≥ 6 cycles of first-line standard chemotherapy and still unresectable. In safety lead-in phase (SP), patients (pts) were orally administered with Fru (4 mg, QD, d1-21, Q4W) plus Cap (850 mg/m2, BID, d1-7 and d15-21, Q4W). In expansion phase, pts were randomized in a 1:1 ratio between FC (Arm A) and Cap (Arm B) only. The primary objectives were to characterize safety, confirm the recommended phase 2 dose (RP2D; in phase SP), and evaluate the efficacy (in phase EP).
Results
As of April 24, 2023, 22 pts were enrolled (SP: n = 6; EP: Arm A/B n/n = 7/7). In phase SP, 1 pt experienced DLT of grade 3 oral mucositis. The treatment emergent AEs (TEAEs, Grade ≥3) were hypertension (1/6), oral mucositis (1/6), voice alteration (1/6), small intestinal obstruction (1/6) and blood bilirubin increased (1/6). After full consideration about patient’s tolerance and safety, the RP2D of Fru was adjusted from 4mg to 3mg through charrette. In Arm A, the most common TEAEs (Grade ≥3) were merely hypertension and leukopenia. Intriguingly, these results provided further evidence that reducing RP2D from 4 mg to 3mg can ensure the safety and tolerance. In 6 evaluable pts of phase SP, the DCR was 100% while the mPFS was immaturity, but 3 pts showed the PFS of ≥ 6 months (7.5, 8.6, 8.9 mon, respectively).
Conclusions
The combination of fruquintinib plus capecitabine demonstrated an acceptable tolerability profile. Preliminary antitumor activity was observed in pts with mCRC that revealed promising efficacy and safety as a first-line maintenance therapy. Dose expansion is ongoing at the RP2D in dedicated mCRC.
Clinical trial identification
NCT05451719.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11